223797-65-7

Basic information

• Product Name: 3-Chloro-5-ethoxypyridine
• Synonyms: 3-Chloro-5-ethoxypyridine
• CAS NO: 223797-65-7
• Molecular Formula: C7H8ClNO
• Molecular Weight: 157.6
• Mol File: 223797-65-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Chloro-5-ethoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-5-ethoxypyridine(223797-65-7)
• EPA Substance Registry System: 3-Chloro-5-ethoxypyridine(223797-65-7)

Safety Data

• Hazardous Substances Data: 223797-65-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-5-ethoxypyridine is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its versatile reactivity allows for the creation of new compounds with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Chloro-5-ethoxypyridine serves as a precursor in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Organic Synthesis:
3-Chloro-5-ethoxypyridine is utilized as a valuable building block in organic synthesis, particularly for the production of heterocyclic compounds. Its unique structure facilitates a range of chemical reactions to generate diverse organic molecules with various applications.
Safety Note:
Due to its potential to cause irritation to the skin, eyes, and respiratory system, 3-Chloro-5-ethoxypyridine should be handled with caution, adhering to proper safety protocols during its use in research and industrial applications.

Upstream product

• 2457-47-8 3,5-dichloropyridine 
• 141-52-6 sodium ethanolate 
• 74115-12-1 5-chloropyridin-3-ol 
• 75-03-6 ethyl iodide 

Downstream Products

• 223795-11-7 1-(5-ethoxy-pyridin-3-yl)-piperazine 
• 51468-00-9 5-ethoxy-pyridin-3-ylamine 

Relevant articles and documents

Regioselective Amination or Alkoxylation of Halogenated Amino-, Thio- or Alkoxypyridines via Pyridyne Intermediates

The treatment of 3-halopyridines (Cl, Br) bearing an R-substituent in position 2 (R = OEt, NEt2, N-piperidyl, or SEt) or in position 5 (R = OMe, OEt, SEt, NMe2, NEt2, or aryl) with KHMDS and an amine at 25 C for 12 hours in THF provided regioselectively 3

Creating an antibacterial with in vivo efficacy: Synthesis and characterization of potent inhibitors of the bacterial cell division protein FTSZ with improved pharmaceutical properties

3-Methoxybenzamide (1) is a weak inhibitor of the essential bacterial cell division protein FtsZ. Alkyl derivatives of 1 are potent antistaphylococcal compounds with suboptimal drug-like properties. Exploration of the structure-activity relationships of analogues of these inhibitors led to the identification of potent antistaphylococcal compounds with improved pharmaceutical properties.

New ligands with affinity for the α4β2 subtype of nicotinic acetylcholine receptors. Synthesis, receptor binding, and 3D-QSAR modeling

A new series of piperazines, diazepanes, diazocanes, diazabicyclononanes, and diazabicyclodecanes with affinity for the α4β 2 subtype of nicotinic acetylcholine receptors were synthesized on the basis of results from a previous computational study. A predictive 3D-QSAR model was developed using the GRID/GOLPE approach (R2 = 0.94, Q 2 = 0.83, SDEP = 0.34). The SAR was interpreted in terms of contour maps of the PLS coefficients and in terms of a homology model of the α4β2 subtype of the nicotinic acetylcholine receptors. The results reveal that hydrogen bonding from both hydrogens on the protonated amine and from the pyridine nitrogen to a water molecule as well as van der Waals interactions between the substituent bearing the protonated amine and the receptor is of importance for ligand affinity. The combination of 3D-QSAR and homology modeling proved successful for the interpretation of structure-affinity relationships as well as the validation of the individual modeling approaches.

BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5

The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.

Novel heteroaryl-diazabicycloalkanes

The present invention relates to novel heteroaryl-diazabicycloalkanes which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment

Heteroaryl diazabicycloalkanes, their preparation and use

The present invention relates to novel heteroaryl diazabicycloalkane derivatives represented by general formula (I), any of its enantiomers or any mixture thereof, an N oxide thereof, a pharmaceutically acceptable salt thereof, in a labelled or un-labelled form, which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis

In the past few years the focus on central acetylcholine receptors has shifted from-compounds with affinity for muscarinic acetylcholine receptors (mAChR) to compounds with affinity for nicotinic acetylcholine receptors (nAChR). The therapeutic potential